HY 014B11
Alternative Names: HY-014B11Latest Information Update: 14 Jun 2021
At a glance
- Originator Helperby Therapeutics
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Intra-abdominal infections; Urinary tract infections
Most Recent Events
- 14 Jun 2021 Helperby Therapeutics plans a preclinical trials for Intra-abdominal infections, Urinary tract infections (Complicated) (Helperby Therapeutics pipeline, June 2021)
- 27 Oct 2020 Early research in Intra-abdominal infections in United Kingdom (PO) prior to October 2020 (Helperby Therapeutics pipeline, October 2020)
- 27 Oct 2020 Early research in Urinary tract infections (Complicated) in United Kingdom (PO) prior to October 2020 (Helperby Therapeutics pipeline, October 2020)